Sartorius Stedim Biotech : successfully places note loan with a volume of 750...
September 09, 2020 at 08:10 am EDT
Share
Press Release
Göttingen, September 9, 2020
Sartorius successfully places note loan with a volume of 750 million euros
Transaction oversubscribed more than three times
Volume increased from 300 million euros to 750 million euros
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully placed a note loan with a volume of 750 million euros. The note loan was issued with maturity terms of 3, 5, 7 and 10 years and was significantly oversubscribed. "We see such great interest as clear proof of our attractiveness for investors," said Rainer Lehmann, Chief Financial Officer of Sartorius.
In view of high demand, the targeted minimum volume of 300 million euros was significantly exceeded. Most of the funds will be used for early repayment of the bridge loan that Sartorius had taken out at the end of April in connection with the acquisition of selected life science businesses from Danaher.
This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.
Contact
Timo Lindemann Corporate Communications +49 (0)551.308.4724 timo.lindemann@sartorius.comsartorius.com
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Sartorius Stedim Biotech SA published this content on 09 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2020 12:09:03 UTC
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
SARTORIUS STEDIM BIOTECH 
